Atara Biotherapeutics (ATRA) Price & Analysis

Compare

1,162 Followers

ATRA Stock Chart & Stats

$15.79

-$1.12(-6.68%)

At close: Jan 08 4:00 PM EST

$15.79

-$1.12(-6.68%)

Day’s Range― - ―

52-Week Range$5.01 - $18.71

Previous CloseN/A

Volume32.09K

Average Volume (3M)59.56K

Market Cap

$105.05M

Enterprise Value$131.17M

Total Cash (Recent Filing)$13.71M

Total Debt (Recent Filing)$58.60M

Price to Earnings (P/E)6.6

Beta0.64

Next Earnings

Nov 18, 2025

EPS Estimate

-0.67

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.19

Shares Outstanding7,210,235

10 Day Avg. Volume63,491

30 Day Avg. Volume59,558

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)-1.02

Price to Sales (P/S)0.77

P/FCF Ratio-1.45

Enterprise Value/Market Cap1.25

Enterprise Value/Revenue0.86

Enterprise Value/Gross Profit1.06

Enterprise Value/Ebitda4.30

Forecast

1Y Price Target

$17.50

Price Target Upside10.83% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)2.43

Revenue Forecast (FY)$121.21M

Bulls Say, Bears Say

Bulls Say

Financial PerformanceAtara recorded a significant improvement in financial results for 2Q25, with net earnings per share far exceeding prior forecasts.

Milestone PaymentApproval of tab-cel will trigger a $40M milestone, providing much-needed cash that could restart Atara's allogeneic CAR T program for autoimmune disease.

Regulatory ApprovalAnalyst remains optimistic about the likelihood of FDA approval for tab-cel, as EBV+ PTLD is an ultra-rare indication and Atara has been able to address manufacturing concerns raised by the FDA.

Bears Say

Investment CaseDespite developments with tab-cel, the analyst does not see a compelling investment case at this time and reiterates a Neutral rating without a price target.

Regulatory RisksRisks include the potential rejection of the tab-cel BLA resubmission by the FDA and setbacks with other pipeline candidates.

Atara Biotherapeutics News

Atara Biotherapeutics price target raised to $18 from $16 at Mizuho

Mizuho analyst Salim Syed raised the firm’s price target on Atara Biotherapeutics (ATRA) to $18 from $16 and...

7d ago

ATRA

Atara Biotherapeutics price target raised to $140 from $131 at Mizuho

Mizuho analyst Salim Syed raised the firm’s price target on Atara Biotherapeutics (ATRA) to $140 from $131 and...

7d ago

ATRA

Atara Biotherapeutics reports Q3 EPS (32c), consensus (67c)

Reports Q3 revenue $3.45M, consensus $2.74M. The company said, “As previously communicated, Atara continues to actively explore and...

15d ago

ATRA

Atara Biotherapeutics reduces workforce by 29%

The company said, “In October 2025, Atara announced a reduction in its workforce that impacted approximately 29% of...

15d ago

ATRA

Pierre Fabre announces transfer of BLA for tabelecleucel from Atara Biotherapeutics

Pierre Fabre Pharmaceuticals announces the transfer of the Biologics License Application for tabelecleucel from Atara Biotherapeutics (ATRA) with...

24d ago

ATRA

ATRA Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Atara Biotherapeutics Inc (ATRA) is scheduled to report 3rd quarter earnings on 11/29/2025, before the market opens. Regarding...

13h ago

ATRA

Potential FDA Approval of Atara’s Tab-cel Therapy: A Game-Changer for Future Growth and CAR T Program Revitalization

Atara Biotherapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst John Newman from...

14d ago

ATRA

Atara Biotherapeutics Announces Significant Workforce Reduction

An announcement from Atara Biotherapeutics ( ($ATRA) ) is now available. On October 6, 2025, Atara Biotherapeutics announced...

2M ago

ATRA

Atara Biotherapeutics Reduces Board Size, Appoints New Chair

Atara Biotherapeutics ( ($ATRA) ) has issued an update. On September 2, 2025, Atara Biotherapeutics announced a strategic...

3M ago

ATRA

Atara Biotherapeutics: Hold Rating Amid Tab-cel Developments and Financial Uncertainty

H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on ATRA stock, giving a Hold rating on...

3M ago

ATRA

Atara Biotherapeutics reports Q2 EPS 19c vs. ($3.10) last year

Cash, cash equivalents and short-term investments as of June 30, 2025, totaled $22.3 million, as compared to $13.8...

4M ago

ATRA

ATRA Upcoming Earnings Report: What to Expect?

Atara Biotherapeutics Inc (ATRA) is scheduled to report 2nd quarter earnings on 08/11/2025. Regarding Q2 estimates, Wall Street...

4M ago

ATRA

Atara Biotherapeutics announces FDA acceptance of tabelecleucel BLA

Atara Biotherapeutics (ATRA) and Pierre Fabre Pharmaceuticals, or PFP, announced the acceptance by FDA of the Biologics License...

4M ago

ATRA

Atara Biotherapeutics announces FDA acceptance of BLA for tabelecleucel

Atara Biotherapeutics (ATRA) announced that the FDA has accepted the filing of its biologics license application for tabelecleucel...

4M ago

ATRA

ATRA FAQ

What was Atara Biotherapeutics Inc’s price range in the past 12 months?

Atara Biotherapeutics Inc lowest stock price was $5.00 and its highest was $18.70 in the past 12 months.

What is Atara Biotherapeutics Inc’s market cap?

Atara Biotherapeutics Inc’s market cap is $105.05M.

When is Atara Biotherapeutics Inc’s upcoming earnings report date?

Atara Biotherapeutics Inc’s upcoming earnings report date is Nov 18, 2025 which is 9 days ago.

How were Atara Biotherapeutics Inc’s earnings last quarter?

Atara Biotherapeutics Inc released its earnings results on Aug 11, 2025. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of -$0.066 by $0.256.

Is Atara Biotherapeutics Inc overvalued?

According to Wall Street analysts Atara Biotherapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Atara Biotherapeutics Inc pay dividends?

Atara Biotherapeutics Inc does not currently pay dividends.

What is Atara Biotherapeutics Inc’s EPS estimate?

Atara Biotherapeutics Inc’s EPS estimate is -0.67.

How many shares outstanding does Atara Biotherapeutics Inc have?

Atara Biotherapeutics Inc has 7,210,235 shares outstanding.

What happened to Atara Biotherapeutics Inc’s price movement after its last earnings report?

Atara Biotherapeutics Inc reported an EPS of $0.19 in its last earnings report, beating expectations of -$0.066. Following the earnings report the stock price went up 11.822%.

Which hedge fund is a major shareholder of Atara Biotherapeutics Inc?

Currently, no hedge funds are holding shares in ATRA

Atara Biotherapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-78.86%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Atara Biotherapeutics Inc

Atara Biotherapeutics (ATRA) is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients with serious diseases, particularly cancer and autoimmune disorders. The company operates primarily in the biopharmaceutical sector, leveraging advanced science to create T-cell therapies that harness the body's immune system to target and eradicate disease. Atara's core products include its lead investigational therapies, which utilize allogeneic T-cell immunotherapy derived from donor cells, aimed at treating various malignancies and chronic viral infections.

Atara Biotherapeutics (ATRA) Earnings & Revenues

Historic Earnings Reports

ATRA Stock 12 Month Forecast

Average Price Target

$17.50

▲(10.83% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","12":"$12","19":"$19","8.5":"$8.5","15.5":"$15.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,8.5,12,15.5,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.85,15.092307692307692,15.334615384615384,15.576923076923077,15.819230769230769,16.06153846153846,16.303846153846152,16.546153846153846,16.78846153846154,17.03076923076923,17.27307692307692,17.515384615384615,17.75769230769231,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.85,15.053846153846154,15.257692307692308,15.461538461538462,15.665384615384616,15.86923076923077,16.073076923076922,16.276923076923076,16.48076923076923,16.684615384615384,16.888461538461538,17.092307692307692,17.296153846153846,{"y":17.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.85,15.015384615384615,15.180769230769231,15.346153846153847,15.51153846153846,15.676923076923076,15.842307692307692,16.007692307692306,16.173076923076923,16.338461538461537,16.503846153846155,16.66923076923077,16.834615384615386,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.36,"date":1719792000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":10.4,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.71,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.14,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":13.31,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.91,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.34,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.45,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.85,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >